The European Union's medicines regulator on Thursday warned countries that malaria drugs being used experimentally to treat the new coronavirus have potentially serious side effects, including seizures and heart problems.
The European Medicines Agency said in a statement that chloroquine and hydroxychloroquine two medicines embraced by US President Donald Trump and others as a potential COVID-19 treatment are known to cause heart rhythm problems, especially if combined with other drugs.
There is currently no licensed treatment for COVID-19 and dozens of trials are under way globally.
Chloroquine and hydroxychloroquine have long been used to treat malaria and anti-inflammatory diseases like rheumatoid arthritis.
In addition to the heart problems, the two drugs can also cause side effects including liver and kidney damage, seizures, and result in low blood sugar.
"Clinical data are still very limited and inconclusive, and the beneficial effects of these medicines in COVID-19 have not been demonstrated," the EMA said.
It noted that several clinical trials testing the drugs' effectiveness against the coronavirus are using higher than recommended doses, which it said could increase the risk of side effects including abnormal electric activity that could disrupt the heart rhythm.
Earlier this month, part of a study in Brazil was suspended after doctors found one quarter of patients taking chloroquine developed irregular heart rhythms after taking a higher dose.
The EMA reminded doctors and patients to report any suspected side effects from hydroxychloroquine and chloroquine to national authorities.
"These must not be used without a prescription and without supervision from a doctor," the agency said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
